Co-founder/CEO
BEAT Therapeutics
The startup develops DNA Damage Response (DDR) therapies that target aggressive cancers with high treatment resistance and poor survival rates. By enhancing the DNA repair mechanisms in cancer cells, the company aims to provide effective treatment options where conventional therapies have failed.
- Biotechnology
Updated 7 months ago
Funding
Funding rounds are not available yet.
Founders
Product
Features
- The startup develops DNA Damage Response (DDR) therapies that target aggressive cancers with high treatment resistance and poor survival rates. By enhancing the DNA repair mechanisms in cancer cells, the company aims to provide effective treatment options where conventional therapies have failed.